Showing 1471-1480 of 2656 results for "".
- FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet AMD and DMEhttps://modernod.com/news/fda-accepts-application-for-genentechs-faricimab-for-the-treatment-of-wet-amd-and-dme/2479419/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic r
- FDA Accepts Application for Genentech’s Port Delivery System with Ranibizumab (PDS) for Treatment of Wet AMDhttps://modernod.com/news/fda-accepts-application-for-genentechs-port-delivery-system-with-ranibizumab-pds-for-treatment-of-wet-amd/2479322/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). If approved, PDS would be a first-of-its-kind therapeutic approa
- Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosahttps://modernod.com/news/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision-in-11-patients-blinded-by-retinitis-pigmentosa/2479261/Nanoscope Therapeutics announced that vision improvements for all evaluated advanced retinitis pigmentosa (RP) patients persisted through 1 year following a single intravitreal injection in a phase 1/2a clinical study with MCO. “We expect to begin the first randomized, placebo-contro
- Study Finds Pfizer, AstraZeneca’s COVID-19 Vaccines “Highly Effective” Against Indian Varianthttps://modernod.com/news/study-finds-pfizer-astrazenecas-covid-19-vaccines-highly-effective-against-indian-variant/2479237/An analysis by Public Health England (PHE) suggests that two doses of COVID-19 vaccines from Pfizer/BioNTech and AstraZeneca are “highly effective” against the B.1.617.2 coronavirus variant first identified in India, the UK government announced on Saturday, according to a FirstWord re
- Biogen’s Phase 2/3 Gene Therapy Study for XLRP Fails to Meet Primary Endpointhttps://modernod.com/news/biogens-phase-2-3-gene-therapy-study-for-xlrp-fails-to-meet-primary-endpoint/2479216/Biogen announced topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). The XIRIUS study did not meet its primary endpoint of demonstrating a st
- Innovega’s eMacula System Shows Potential to Increase Independence for Visually Impairedhttps://modernod.com/news/innovegas-emacula-system-shows-potential-to-increase-independence-for-visually-impaired/2479190/The use of Innovega eMacula system, which pairs smart contact lenses with display eyewear, demonstrated positive results with partially sighted subjects for their daily tasks, including reading, smart phone use, and distance vision, according to research conducted at The Ohio
- Roche, Regeneron’s REGEN-COV Cuts Symptomatic COVID-19 by 81% Among Household Contactshttps://modernod.com/news/roche-regenerons-regen-cov-cuts-symptomatic-covid-19-by-81-among-household-contacts/2479071/Regeneron Pharmaceuticals and partner Roche reported positive results from a phase 3 study, showing that a subcutaneous formulation of the antibody cocktail REGEN-COV (casirivimab with imdevimab) reduced the risk and burden of COVID-19 among household contacts of SARS-CoV-2-
- AstraZeneca’s COVID-19 Vaccine Shows 79% Efficacy in Pivotal US Studyhttps://modernod.com/news/astrazenecas-covid-19-vaccine-shows-79-efficacy-in-pivotal-us-study/2478995/AstraZeneca on Monday announced that its vaccine AZD1222 demonstrated efficacy of 79% at preventing symptomatic COVID-19 in a late-stage study conducted in the US. Results also showed that the vaccine had 100% efficacy at preventing severe disease and hospitalization, with comparable effectivenes
- AAO: Looks Like the Home Office is Here to Stay. Here’s How to Protect Your Eyeshttps://modernod.com/news/aao-looks-like-the-home-office-is-here-to-stay-heres-how-to-protect-your-eyes/2478962/As home and office space merged during the pandemic, many people said they spent more time in front of screens and suffered because of it. They complained of eye strain, headaches, and dry eye, and worried that they might be doing permanent damage to their vision. Now comes a
- Lilly’s Bamlanivimab, Etesevimab Cut Hospitalizations, Deaths in High-Risk COVID-19 Patientshttps://modernod.com/news/lillys-bamlanivimab-etesevimab-cut-hospitalizations-deaths-in-high-risk-covid-19-patients/2478961/Eli Lilly reported new phase 3 results demonstrating that the antibody cocktail containing bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with SARS-CoV-2 infection. “These positive results reinforce our